Anti-vertebral fracture efficacy of raloxifene: A meta-analysis

Osteoporosis International

Volumn 17, Issue 2, 2006, Pages 313-316

  Seeman, Ego ^a   Crans, Gerald G ^b   Diez Perez, Adolfo ^c   Pinette, Karen V ^b   Delmas, Pierre D ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Meta analysis; Osteoporosis; Raloxifene; Vertebral fracture

Indexed keywords

RALOXIFENE;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; MEDLINE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ODDS RATIO; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SPINAL FRACTURES;

EID: 30144444881     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-2030-1     Document Type: Article

References (9)

1. NIH consensus development panel on osteoporosis prevention data (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
2. Chesnut CH, III, Rosen CJ (2001) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163-2172
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
4. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23:524-528
5. Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10:337-344
6. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793-800
7. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754
8. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516
9. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634